close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

19.91 +0.94 (+4.96%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q3 2026, with sales flat year on year at $3.75 billion. On the ot... 
Via StockStory
News headline image
Viatris (VTRS) Q3 2026 Earnings Call Transcript ↗
Nashik supply hits weighed on quarterly results, yet guidance rose. 
Via The Motley Fool
Topics Earnings
News headline image
Viatris (NASDAQ:VTRS) misses Q3 2026 sales expectations but beats adjusted EPS consensus estimates
Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q3 2026, with revenue flat year on year at $3.75 billion. On the other ... 
Via StockStory
Viatris (NASDAQ:VTRS) Q3 2026 Earnings: Profit Beat Offset by Revenue Miss ↗
Via Chartmill
News headline image
Viatris (VTRS) Q3 earnings report preview: what to look for
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what investors should know. Viatris be... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 stock under $50 worth investigating and 2 we ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
Topics Energy
News headline image
1 cash-producing stock with competitive advantages and 2 we brush off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
S&P 500 After-Hours Movers: Oct. 20 Gainers and Decliners ↗
Via Chartmill
Topics Stocks
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Why Pacira BioSciences Skyrocketed Today ↗
The specialty pharmaceutical company is being acquired. 
Via The Motley Fool
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Monday. ↗
Via Chartmill
News headline image
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
3 S&P 500 Stocks We Keep Off Our Radar
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Fraud Stocks
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
Viatris (VTRS) Q2 2026 Earnings Call Transcript ↗
Greater China surges 16% as management raises full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectatio... 
Via StockStory
Topics Earnings Economy
News headline image
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company e... 
Via StockStory
Topics Economy
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion.... 
Via StockStory
News headline image
Viatris (VTRS) Q2 Earnings Report Preview: What To Look For
Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before the bell. Here’s what to look for. Viatris beat analysts’ revenue ex... 
Via StockStory
Topics Artificial Intelligence
News headline image
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thank... 
Via StockStory
News headline image
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Stock Under $50 to Target This Week and 2 We Avoid
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.